Experimental models of sepsis and septic shock: an overview

Modelos experimentais de sepse e choque séptico: revisão

SPECIAL ARTICLE

Experimental models of sepsis and septic shock: an overview¹

Modelos experimentais de sepse e choque séptico: revisão

Alejandra G. Garrido^I; Luiz Francisco Poli de Figueiredo^II; Maurício Rocha e Silva^III

^IDoutor pelo Curso de Pós-graduação em Anestesiologia, FMUSP

^IIProf. Associado, Depto. Cardiopneumologia, InCor, FMUSP e Depto Cirurgia Universidade Federal de São Paulo - Escola Paulista de Medicina (UNIFESP-EPM)

^IIIProf. Titular, Depto. Cardiopneumologia, InCor, FMUSP

^{Correspondence}

ABSTRACT

Sepsis remains a major cause of morbidity and mortality in surgical patients and trauma victims, mainly due to sepsis-induced multiple organ dysfunction. In contrast to preclinical studies, most clinical trials of promising new treatment strategies for sepsis have fails to demonstrate efficacy. Although many reasons could account for this discrepancy, the misinterpretation of preclinical data obtained from experimental studies, and especially the use of animal models that do not adequately mimic human sepsis may have been contributing factors. In this review, the benefits and limitations of various animal models of sepsis are discussed to clarify the extend to which findings are relevant to human sepsis, particularly with respect to the subsequent design and execution of clinical trials. Such models include intravascular infusion of endotoxin or live bacteria, bacterial peritonitis, cecal ligation and perforation, soft tissue infection, pneumonia or meningitis models, using different animal species including rats, mice, rabbits, dogs, pigs, sheep and nonhuman primates. Despite several limitations, animal models remain essential in the development of all new therapies for sepsis and septic shock, because they provide fundamental information about the pharmacokinetics, toxicity, and mechanism of drug action that cannot be duplicated by other methods. New therapeutic agents should be studies in infection models, even after the initiation of the septic process. Furthermore, debility conditions need to be reproduced to avoid the exclusive use of healthy animals, which often do not represent the human septic patient.

Key words: Animal models. Bacteremia. Endotoxin. Shock. Sepsis.

RESUMO

A sepse persiste como causa capital de mortalidade e morbidade em pacientes operados e nas vítimas de trauma, principalmente pela disfunção de múltiplos órgãos induzida pela sepse. Em contraste com estudos experimentais, a maioria dos estudos clínicos avaliando potenciais novos tratamentos para a sepse falham em demonstrar eficácia. Apesar de haver diversas possíveis explicações para esta discrepância, a interpretação equivocada dos dados pré-clínicos e. principalmente, o uso de modelos animais que não mimetizam adequadamente a sepse humana podem ter sido fatores contribuintes. Nesta revisão, os benefícios e limitações dos diversos modelos experimentais de sepse são discutidos quanto a relevância com a sepse humana e em relação a futuros ensaios clínicos. Entre os modelos discutidos incluímos a injeção intravascular de endotoxina ou bactérias vivas, peritonite bacteriana, ligadura e punção cecal, infecção de tecidos moles, e modelos de pneumonia e meningite, utilizando várias espécies de animais tais como ratos, camundongos, coelhos, porcos, ovelhas e primatas. Apesar das limitações, modelos animais permanecem essenciais para o desenvolvimento de todas as novas terapias para a sepse e choque séptico, pois fornecem dados fundamentais quanto a farmacocinética, toxicidade e mecanismos de ação das drogas e que não podem ser de outro modo reproduzidos. Os novos agentes terapêuticos devem ser testados mesmo após o início do processo séptico e condições debilitantes devem ser desenvolvidas para evitar o uso exclusivo de animais saudáveis e que freqüentemente não representam a maior parte da população de pacientes sépticos.

Descritores: Bacteremia. Choque. Endotoxina. Modelos animais. Sepse.

Introduction

Sepsis is a major cause of morbidity and mortality in surgical patients and trauma victims, in spite of all technical improvements and advances in supportive treatments. Sepsis affects approximately 700.000 people annually and accounts for about 210.000 deaths per year in the United States, contributing to an annual health-care expenditure of $16.7 billion¹.

Sepsis is a clinical syndrome that results from a complex interaction between host and infectious agents, and it is characterized by systemic activation of multiple inflammatory pathways, including cytokine network and coagulation². Hemodynamic changes, widespread microcirculatory disturbances and cellular alterations, leading to an uncoupling between blood flow and metabolic requirements, are implicated in the development of multiple organ dysfunction, responsible for most of deaths³.

Unfortunately, while epidemiologic data show that the incidence is rising at rates between 1.5% and 8% per year¹, there is little evidence of substantial improvement in survival since the 1970s^1,4. This upsurge has been attributed to a host factors, including the increased use of cytotoxic and immunosuppressive therapies, the aging of the population, a heightened frequency of infection from antimicrobial-resistent pathogens, a high prevalence of chronic debility disease and the increased use of invasive devices for diagnostic, treatment and monitoring⁵. In the last three decades, considerable effort and expenses have been spent in animal and clinical studies addressing the pathophysiology and treatment of this syndrome^1,4,6. However, in contrast to preclinical studies, most clinical trials of promising new treatment strategies for sepsis have failed to demonstrate efficacy^2,6-8. Although many reasons could account for this discrepancy, the misinterpretation of preclinical data obtained from experimental studies, and especially the use of animal models that do not adequately mimic human sepsis may have been contributing factors ^1,7,8.

In this review, the benefits and limitations of various animal models of sepsis are discussed to clarify the extent to which findings are relevant to human sepsis, particularly with respect to the subsequent design and execution of clinical trials.

Animal models

Several animal models replicate the signs and laboratory findings seen in human sepsis. Such models include intravascular infusion of endotoxin^9-17 or live bacteria^3,10,18-20, bacterial peritonitis^8,25-31, cecal ligation and perforation^7,32-34, soft tissue infection³⁵, pneumonia model^36,37, and meningitis model³⁸. Different animal species have been used including rats, mice, rabbits, dogs, pigs, sheep and nonhuman primates³⁹. Even though those models replicate many of the features of sepsis, it is important to critically evaluate the extent to which they mimic the septic picture⁴. With this objective, we present some of the important features of the sepsis models that have been currently used.

Endotoxicosis models

Endotoxin is commonly used in animal models of sepsis, although there is controversy over their relevance to our understanding of human sepsis. When administered to human subjects, endotoxin may mimic many of the features of sepsis³⁹. In critically ill patients, increased concentrations of serum endotoxin have been associated with the development of sepsis, disease severity, and mortality^4,6,39. Detectable levels of LPS are identified in up to 75 per cent of patients with sepsis in intensive care setting⁴⁰. Serum endotoxin levels often remain undetectable in more indolent forms of uncomplicated sepsis with the recorded levels being of no prognostic significance⁴. Very high levels are occasionally found in meningococcemia and at the start of bactericidal antibiotic therapy⁴¹. The plausibility of the hypothesis that endotoxin plays a significant role in the pathogenesis of sepsis is supported by many studies that show that antibiotic administration may lead to an sudden release of massive amounts of endotoxin from dead bacteria and an acute hemodynamics worsening^4,6,18,32,41.

Endotoxin or lipopolysaccharide (LPS), the principal component of the gram-negative bacterial cell wall, stimulates the release of inflammatory mediators from various cell types, responsible for initiating the process of sepsis^6,39. LPS is a stable, relatively pure compound that can be stored in lyophilized form. An accurate dose can be measured and may be administered as a bolus or infusion³⁹. This has formed the basis for the simplest sepsis model and many endotoxicosis models have been described⁴⁰.

There are considerable differences between species in sensitivity to endotoxin. Rodents, cats and dogs are relatively endotoxin resistant, whereas humans and other animals (rabbits, sheep and nonhuman primates) show an enhanced response^4,39,42. In insensitive animals, presensitization with killed organism or D-galactosamine reduces the dose of LPS needed to produce an inflammatory response⁴⁰. Despite lower doses being more physiological, most endotoxicosis studies have continued to use high doses in non-sensitized animals. The duration and route of administration have varied between studies.

A large intravenous dose of LPS in rats produces rapid cardiovascular collapse and early death¹¹, whereas lower doses produces a hyperdynamic response with an early increase in cardiac output¹². Similarly, rabbits challenged with high-doses of LPS (5mg/Kg), develop a hypodynamic circulatory pattern with low cardiac output and high systemic vascular resistance, and when challenged with much smaller dose (1-3ug/Kg), they manifest a hyperdynamic state³⁹. In sheep, low dose of LPS (0.75ug/Kg) results in a biphasic response characterized by an early reduction and late increase in cardiac output¹³, whereas prolonged extremely low-dose of LPS (9, 12 or 24ng/Kg-hr for 24 hr) produces a delayed hyperdynamic state characterized by an increased cardiac output and vasodilatation¹⁴. As is the case in human sepsis, higher dosage of endotoxin in sheep has been associated with a more profound myocardial depression⁹. Endotoxin administration in dogs (2mg/Kg) provokes a severe hypodynamic state with a sharp decrease in arterial pressure, cardiac output, hepatic blood flow, and an increase in systemic vascular resistance and blood lactate levels¹⁵. Most nonhuman primate endotoxicosis models have used massive intravenous doses that resulted in rapid circulatory collapse and early death, while a low dose more closely resembled human sepsis with coagulopathy and progressive multiorgan dysfunction¹⁶.

In spite of evidences that endotoxin may play an important role in the pathogenesis of sepsis, several authors have expressed concerns that the infusion of endotoxin is not a suitable model to study sepsis^4,39. These concerns are based on a number of observations: a) it is likely that the use of endotoxin, in high doses in animals that are resistant to endotoxin, has toxic effects that are not seen when low doses are administered to endotoxin sensitive species, such as man⁴; b) endotoxin, although released by gram-negative sepsis, is not released in gram-positive bacteria, and yet mortality for these infections is similar⁶, and c) administrations of corticosteroids¹⁷ and anti-TNFa⁴³ have been shown to be effective in animal models of endotoxemia, but then failed to show efficacy when used in clinical trials^4,6,7,44. Moreover, it has been demonstrated that killed E. coli are much more lethal than endotoxin. As the endotoxin is only one component of gram-negative bacteria, it is theorized that the other cell wall components also contribute to systemic inflammatory response⁴⁴.

Thus, caution is needed in assessing the clinical efficacy of novel therapeutic agents in animal models of endotoxemia⁴. Currently, there is general agreement among researchers that LPS injection may serve as a model for endotoxic shock but not for sepsis^1,39.

Intravascular infusion of live bacteria

Sepsis is a syndrome that usually evolves in a spectrum from systemic inflammatory response to septic shock. With increasing disease severity, the frequency rate of positive blood cultures increases (sepsis [17%], severe sepsis [25%], septic shock [69%]), therefore several studies suggest that bacteremia may play an important role in determining outcome in sepsis³⁹.

Several studies have investigated the response to intravenous administration of live bacteria⁴⁴. Many different aerobic bacterial species have been investigated; Escherichia coli is the most common. As with endotoxicosis models, the dose of organism and duration of infusion have varied considerably between models.

In small mammals, low doses of E. coli, administered over several hours, have been associated with minimal early physiological changes, while higher doses have often produced a biphasic response with an early rise and late fall in cardiac output⁴⁰.

In large mammals studies, higher microbiological doses have invariably been used. In baboons, the intravenous LD₁₀₀ dose of E. coli, as a bolus, induced an exaggerated TNFa response with cardiovascular collapse and early death. In this model, pretreatment with a TNFa inhibitor improved hemodynamic performance and survival, confirming the role of TNFa in cardiovascular collapse with subsequent organ damage and death, observed in sepsis²¹. Recently, Taylor described a severe disseminated intravascular coagulation induced by both sublethal and lethal dose of live E. coli and endotoxin in baboons¹⁰. This threatening condition results from a complex inflammatory and hemostatic response that involve the microvascular endothelium and its regulatory anticoagulant networks, and contributes to development of a multiorgan dysfunction¹⁰.

Interestingly, in a porcine model using both gram-positive and gram-negative bacteria at the same dose, the hemodynamic and pulmonary changes depended on the bacterial species used. While Staphylococcus aureus induced minimal changes, both E. coli and P. aeruginosa resulted in shock and acute respiratory failure²².

In an ovine model, a nonlethal dose of E. coli promoted a hyperdynamic cardiovascular response with hypotension, increased output, tachycardia, fever, oliguria, tachypneia and hyperlactatemia³. In a porcine model, P. aeruginosa infused over a week resulted in biphasic changes to the cardiac output, with late systemic hypotension and pulmonary hypertension²³.

In dogs, both sublethal and lethal intravenous dose of live E. coli promoted early profound cardiovascular deterioration with hypotension, very low cardiac output, splanchnic hypoperfusion and severe metabolic changes^19,20. Animals challenged by a lethal dose of E. coli (1.2 x 10¹⁰ cfu/Kg) presented only partial and transient improvements in systemic and regional blood flows during fluid resuscitation, but the progressive cardiovascular collapse was unavoidable (Figure 1).

In this model, the magnitude of regional changes was greater than systemic alterations. Moreover, the transient benefits after fluid replacement were much less evident within the splanchnic region, in special at microcirculatory level, as demonstrated by the PCO₂-gap (Figure 1). This discrepancy between systemic and regional parameters has been well demonstrated in experimental and clinical studies^19,45. The intense compromise of splanchnic perfusion, particularly at the gut mucosa, has been implicated in the genesis, amplification and perpetuation of the systemic inflammatory response and the progression of multiple organ dysfunction⁴⁶. The pathophysiologic basis that has been used to explain this phenomenon is that the gut hypoxia and/or ischemia contribute to gastrointestinal tract barrier dysfunction and translocation of cytokines, bacteria and their products⁴⁷.

At the time of autopsy, all animals showed evidence of major inflammatory alterations and injury in lungs and liver²⁰. An illustrative example of the major histological impact of this model of septic shock is presented in Figure 2. Tissue inflammatory recruitment, presence of small vessel thrombosis, vascular congestion, focal hemorrage and microabscess were observed in lung and liver parenchymas. These alterations have been described in experimental and clinical sepsis⁴⁸, and reflect the complex host systemic response with activation of multiple inflammatory pathways and the coagulation system contributing to widespread microcirculatory disturbances.

The acute intravenous live bacteria injection results in immediate cardiovascular collapse and early death, behavior rarely seen in human sepsis. However, this model presents a great value. First, it may mimic extreme clinical sepsis such as seen in meningococcemia, pneumococcal bacteremia in asplenic individuals and gram-negative bacteremia in the setting of profound granulocytopenia³⁹, the two last clinical pictures are increasing nowadays. Second, this model allows the study of the acute effects of interventions in short periods, reducing the expenses in the research. Third, large animals allow the use of systemic and regional monitoring similar to the ones used in intensive care units, in addition to regional blood flow measurements and blood sampling only feasible in experimental studies.

As in other models, the hemodynamic response to the challenge with live bacteria, also depends on fluid resuscitation and antibiotic treatment. The use of fluid resuscitation has varied between studies but, in its absence, early death was often reported. There is considerable evidence that antibiotic may, through the massive bacteria destruction and release of substantial amounts of cell wall components by gram-negative, gram-positive and fungi, promotes an intense inflammatory response with excessive high levels of TNFa causing hemodynamic deterioration, specially in the absence of fluid resuscitation^18,32,41.

Not all models using an intravascular infusion of live bacteria are acute preparations characterized by cardiovascular collapse secondary to overwhelming bacteremia. Shaw and Wolfe described a chronically instrumented unastestetized canine model wherein animals were infused intraarterially with viable E. coli and studied 24 hr later. The animals were aggressively resuscitated at the time sepsis was induced, the dose of bacteria being invariably lethal in the absence of adequate restoration of intravascular volume. However, with the fluid resuscitation, 85% of the animals survived the protocol and, at the time of study, were hyperdynamic and hypermetabolic²⁴. Additionally, many of the hormonal perturbations typically in septic humans were observed. Although not widely utilized, this model mimics many of the features of clinical sepsis and avoids the confounding effects of anesthesia and surgical preparations.

Since most patients are not challenged with a massive bacterial load at any time, but rather harbor a septic focus that is intermittently and persistently, showering the body with bacteria, several authors have questioned the relevance of models utilizing a bolus infusion of viable bacteria³⁹.

Additionally, concerns over the use of an appropriate strain of an infective organism extend also to studies of endotoxemia where the most commonly used strain of endotoxin is uncommonly seen in human bacteremia. There are a number of features of either the host or host-bacterium interactions that are species-specific⁴. For example, Salmonella typhi does not cause systemic infection in laboratory rodents but is responsible for typhoid fever in humans. In mice, a related bacterium, Salmonella typhimurium, causes a systemic infection and it is commonly used as a model of human typhoid infection, despite its low virulence in humans⁴. Individual bacteria may also cause a broad spectrum of disease process depending on the expression of virulence genes. These findings suggest that it may be difficult to make conclusions regarding the efficacy of a therapy based on a study looking at infection with a single bacteria strain, particularly if it is a pathogen not commonly seen in critically ill patients⁴.

Despite these criticisms, numerous laboratories continue to utilize intravascular infusions of viable bacteria to induce sepsis in animals, and many of these models remain very useful, provided that certain inherent limitations are recognized³⁹.

Peritonitis models

Peritonitis may be induced in animals in several ways. Bowel can be perforated allowing contamination with gastrointestinal contents, or inoculum of fecal material or pure bacterial cultures can be instilled into the peritoneal cavity⁴⁰.

In early models, segments of intact bowel were isolated and the development of peritonitis was expected⁴⁰. The disadvantage of this method was that the onset of peritonitis was uncontrolled and depended on the timing of gastrointestinal perforation. To overcome this limitation, the simple and reproducible cecal ligation and puncture model (CLP) was developed and has been used widely in sepsis research³³. The cecum is ligated distal to the ileocecal valve and perforated using two needle punctures. Needle size can be used to manipulate CLP to give a lethal and nonlethal sepsis⁷. The model was originally described in rats, but has been extended successfully to other species^32,34.

The principal advantage of CLP models is their simplicity. Since sepsis is induced by a straightforward surgical procedure, there is no need to grow and quantify bacteria or in other ways prepare the inoculum. Furthermore, these are models of sepsis due to peritoneal contamination with mixed flora in the presence of devitalized tissue and thus bear an obvious resemblance to clinical problems like perforated appendicitis and diverticulitis⁴⁰. This technique, without fluid resuscitation, promotes rapid onset of shock, while after fluid resuscitation the mortality rate may be reduced with pathophysiological responses resembling those noted in human sepsis³².

However, in CPL model, it is difficult to control the magnitude of the septic challenge. In studies using small animals (mice and rats), the problem of variability is easily overcome by increasing sample size; whereas, variability remains a problem in larger species.

The gastrointestinal contents of animals, particularly herbivores, vary between species. Initial attempts at inducing peritonitis by intraperitoneal implantation of feces were often disappointing, with animals appearing tolerant to their own fecal flora⁴⁰. To overcome those limitations, human feces were used, or barium sulphate, bile salts, or autologous haemoglobin added to the fecal material⁸. Polymicrobial peritonitis induced in rats, by a standard inoculum of pooled fecal material derived from several animals, produced a hyperdynamic sepsis response, with a high mortality rate in unresuscitated animals²⁸. The advantages of this model include good reproducibility and the possibility to study dose-response relationship both systemically and in remote organ systems, where the intensity and the kinetics of systemic and pulmonary inflammatory responses to polymicrobial peritonitis in mice substantially depend on the inoculum size²⁶.

Both cecal ligation and puncture and fecal inoculation models deliver a variable microbiolgical dose⁸, so pure bacterial culture peritonitis models have been developed.

In 1980, Ahrenholz and Simmons showed that 24-hr mortality was 100% when viable E. coli suspended in saline were injected intraperitoneally in rats. However, when the same number of bacteria was implanted intraperitoneally in a bovine clot, early mortality was prevented, but the rats developed abscess and 10-day mortality was 90%²⁹. Thus, fibrin delays the systemic absorption of the entrapped bacteria and promotes the development of chronic intraperitoneal abscess, a more local septic focus³⁹. Based on this original work, a canine model of sepsis, produced by the intraperitoneal implantation of a fibrin clot containing viable E. coli, was developed³⁰. This highly reproducible model, has been described in small and large mammals^8,27,31, and displays many features of human sepsis including insidious onset, hyperdynamic cardiovascular state^8,31, reversible left ventricular dilatation with impaired systolic performance³¹, and a significant mortality rate^8,25,31.

Unlike other peritonitis models using fecal implantation or cecal ligation/perforation, the fibrin clot model allows the investigator to have complete control over the dose of bacteria and the type of organism implanted³⁹. Some have used single-organism cultures ^8,25,27,31, whereas others have used mixed cultures that more accurately mimic the gastrointestinal flora²⁶. However, a single-organism fails to reproduce the synergy between aerobic and anaerobic organisms seen in human peritonitis, where the aerobic gram-negative organism appear responsible for many of the acute physiological features of sepsis while anaerobes appear to contribute to the development of intraperitoneal abscess⁴⁰.

Limitations of all sepsis models

Animal models have been chosen largely on the basis of traditional practices, familiarity of individual investigator, economic considerations, availability, and ethical acceptability. Rodents should generally be the animals of choice at the beginning of preclinical investigations⁴. Yet rodents are quite endotoxin resistant, have limited vascular access and blood volume, and have cardiovascular physiologies that differ substantially from humans^1,42.

Endotoxemia and bacteremia represent models without an infectious focus. They reproduce many characteristics of sepsis and are highly controlled and standardized. However, they reflect a primarily systemic challenge and create neither an infectious focus nor the protracted immune reaction that characterizes sepsis. In this respect, any model with an infectious focus is decisively closer to clinical reality⁴⁹.

In most animal models of infection, gram-negative bacteria have been used. This does not reflect the diversity of infectious agents, sites of infection, and progress of the infection encountered clinically. For example, in recent clinical trials, gram-positive organisms and fungi have exceeded gram-negative organisms as a cause of sepsis, but they are infrequent in animal studies⁶. Additionally, there is an increasing concern about possible important differences in host inflammatory responses to sepsis due to gram-positive versus gram-positive bacteria^6,18. Experimental evidences suggest that the efficacy of mediator-specific anti-inflammatory agents in sepsis may be altered by the bacteria type of underlying infection with significant differences between gram-negative and gram-positive strains⁶. Recently, the use of antibody to TNFa improved the host defense and survival rates with both lethal E. coli and S. aureus pneumonia, but the protection was greater with E. coli, where TNF concentrations were higher than with S. aureus³⁷.

In some experimental models, anticytokine therapy has been effective in the setting of systemic intravascular challenge with live bacteria or endotoxin, but is of little benefit, or potentially harmful, in models of localized infection²⁵. Intravenous challenge, due to the relatively large inoculum required, probably constitutes a model of endotoxin intoxication rather than evolving infection. Intraperitoneal challenges typically require 100- to 1000-fold fewer bacteria¹. Thus, the models used most extensively do not precisely replicate many important clinical parameters and do not duplicate the dynamic interactions among investigational drugs, microbial pathogens, and host defenses that occur in patients with sepsis.

While promising agents are studied later in larger animals, including primates, and attempts are made to mimic various aspects of human septic shock, the experimental conditions encountered in human sepsis trials are more complicated than simulated even in large-animal models. Animals are carefully selected to have no intercurrent illnesses, and to be similar genetic background, age, weight, gender, and nutritional status⁴². These animals are then challenged with a single, well-defined, precipitating event. In contrast, patients with sepsis are heterogeneous with respect to age, preexisting conditions, sources of infection, types of infecting microorganism, and many of them have experienced trauma or major surgery⁴². Adequacy of care, including promptness and quality of resuscitation, appropriateness of antibiotics, and timing quality of surgical intervention also determine survival in human settings⁴².

The natural history of severe sepsis in laboratory animals is generally distinct from human sepsis, with animals more often having a rapid onset of hypodynamic circulatory collapse and a more rapid resolution or decline to mortality. In clinical sepsis, the mortality is most commonly due to the development of multiple organ failure, days to weeks after initial presentation. For this reason, animal models that lead to significant mortality within the first 6 to 12 hours may not describe an outcome that is relevant to human⁴.

Agents under investigation are too often administered to animals before or immediately after the septic challenge, conditions that can rarely be achieved in clinical trials⁴.

Finally, nonblinded and/or nonrandomized studies are common in animal research, and introduce an easily avoidable source of bias^1,4. In addition, the desire to demonstrate a therapeutic affect may create experimental conditions that are not clinically realistic.

Conclusions

A major concern is that animal models have demonstrated protective effects that have not been reproduced in subsequent clinical trials. Many of the problems with the use of animal data in sepsis drug development stem, not from the animal models, per se, but from how those results have been adapted to clinical trial design. Animal models provide insights about specific components of the septic process but cannot truly mimic the full clinical complexity and intrinsic heterogeneity of patients with sepsis. Despite these limitations, animal models will remain essential in the development of all new therapies for sepsis and septic shock, because they provide fundamental information about the pharmacokinetics, toxicity, and mechanism of drug action that cannot be duplicated by other methods.

Nonetheless, there is much to be improved in animal experiments. Examples are the need for long-term studies with intensive care unit-like conditions to simulate the often delays onset of organ dysfunction in the clinical setting, using sepsis or organ dysfunction criteria to start treatment instead of a fixed time schedule. New therapeutics agents should be studied in infection models even after initiation of the septic process. Furthermore, debility conditions need to be reproduced to avoid using healthy animals, which often do not represent the human septic patient.

19. Lagoa CE, Poli de Figueiredo LF, Cruz Junior RJ, Silva E, Rocha e Silva M. Effects of fluid resuscitation on splanchnic perfusion in a canine severe sepsis model. Crit Care 2004 (in press).

Data do recebimento: 21/12/2003

Data da revisão: 04/01/2004

Data da aprovação: 19/01/2004

Conflict of interest: none

Financial source: FAPESP

• 1. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003;112:460-7.
• 2. Van der Poll, T. Immunotherapy of sepsis. Lancet Infect Dis 2001;1:165-74.
• 3. Giantomasso DD, May CN, Bellomo R. Vital blood flow during hyperdynamic sepsis. Chest 2003;124:1053-9.
• 4. Piper RD, Cook DJ, Bone RC, Sibbald WJ. Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996;24:2059-70.
• 5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiolgy of severe sepsis in the united estates: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
• 6. Opal SM, Cohen J. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999;27:1608-16.
• 7. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 1999;67:6603-10.
• 8. Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Feuerstein G, Rabinovici R. An improved clinically relevant sepsis model in the conscious rat. Crit Care Med 2000;28:1947-52.
• 9. Pittet JF, Pastor CM, Morel DR. Spontaneous high systemic oxygen delivery increases survival rate in awake sheep during sustained endotoxemia. Crit Care Med 2000;28:496-503.
• 10. Taylor FB. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: Examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 2001;29:S78-89.
• 11. Brackett DJ, Schaefer CF, Tompkins P, Fagraeus L, Peters LJ, Wilson MF. Evaluation of cardiac output, total peripheral resistance, and plasma concentration of vasopressin in the conscious unrestrained rat during endotoxemia. Circ Shock 1985;17:273-84.
• 12. Johnston TD, Hampton WW, Fry DE. Septic hemodynamics produced by infusion of endotoxin. Curr Surg. 1989;46:101-3.
• 13. Talke P, Dunn A, Lawlis L, Sziebert L, White A, Herndon D, Flynn JT, Traber D. A model of ovine endotoxemia is characterized by an increased cardiac output. Circ Shock 1985;17:103-8.
• 14. Traber DL, Redel H, Schlag G, Herndon DN, Kimura R, Prien T, Traber LD. Cardiopulmonary responses to continuous administration of endotoxin. Am J Physiol 1988;254:H833-9.
• 15. Spapen H, Zhang H, Wisse E, Baekeland M, Seynaeve C, Eddouks M, Vincent JL. The 21-Aminosteroid U74389G enhances hepatic blood flow and preserves sinusoidal endothelial cell function and structure in endotoxin- shocked dogs. J Surg Res 1999;86:183-91.
• 16. Lindsey DC, Emerson TR Jr, Thompson TE, John AE, Duerr ML, Valdez CM Kuo HS, Bouffard RB, Irwin RG, Canivel D et al. Characterization of an endotoxemic baboon model of metabolic and organ dysfunction. Circ Shock 1991;34:298-310.
• 17. Nomura S, Harasawa Y, Hayashi S. Antishock effect of U-67, 590A, methylprednisolone suleptanate, associated with restoration of lowered vascular reactivity in entotoxemic rats. J Cardiovasc Pharmacol 1993;22:550-6.
• 18. Silverstein R, Wood JG, Xue Q, Norimatsu M, Horn D, Morrison DC. Differential host inflammatory responses to viable versus antibiotic-killed bacteria in experimental microbial sepsis. Infect Immun 2000;68:2301-8.
• 20. Garrido AG. Efeitos hemodinâmicos sistêmicos e regionais da infusão de cristalóides em modelo experimental de choque séptico hipodinâmico [Tese - Doutorado]. Universidade de São Paulo Faculdade de Medicina; 2003.
• 21. Espat NJ, Cendan JC, Beierle EA, Auffenberg TA, Rosenberg J, Russel D, Kenney JS, Fisher E, Montegut W, Lowry SF, Copeland EM, Moldawer LL. PEG-BP-30 Monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock. J Surg Res 1995;59:153-8.
• 22. Dehring DJ, Crocker SH, Wismar BL, Steimberg SM, Lowery BD, Cloutier CT. Comparison of live bacteria infusions in a porcine model of acute respiratory failures. J Surg Res 1983;34:151-8.
• 23. Haberstroh J, Breuer H, Lucke I, Massarrat K, Fruh R, Mand U, Hagedorn P, Brunnberg L, von Specht BU. Effect of a recombinant human granulocyte colony-stimulating factor on hemodynamic and response in a porcine model of Pseudomonas sepsis. Shock 1995;4:216-24.
• 24. Shaw JH, Wolfe RR. A conscious septic dog model with hemodynamic and metabolic responses similar to responses of humans. Surgery 1984;95:553-61.
• 25. Quezado Z, Natanson C, Alling D, Banks SM, Koev CA, Elin RJ, Hosseini JM, Bacher JD, Danner RL, Hoffman WD. A controlled trial of HA-1A in a canine model of gram-negative septic shock. J Am Med Assoc 1993;269:2221-7.
• 26. Stamme C, Bundschuh DS, Hartung T, Gebert U, Wollin L, Nürsing R, Wendel A, Uhlig S. Temporal sequence of pulmonary and systemic inflammatory response to grade de polymicrobiaal peritonitis in mice. Infect Immun 1999;67:5642-50.
• 27. Goldfarb RD, Marton A, Szabó E, Virág L, Salzman AL, Glock D, Akhter I, McCarthy R, Parrillo JE, Szabó C. Protective effect of a novel, potent inhibitor of poly (adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 2002;30:970-80.
• 28. Lang CH, Bagby GJ, Bornside GH, Vial LJ, Spitzer JJ. Sustained hypermetabolic sepsis in rats: characterization of the model. J Surg Res 1983;35:201-10.
• 29. Ahrenholz DH, Simmons RL. Fibrin in peritonitis. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 1980;88:41-7.
• 30. Fink MP, MacVittie TJ, Casey LC. Inhibition of prostaglandins synthesis restores normal hemodynamics in canine hyperdynamic sepsis. Ann Surg 1984;200:619-26.
• 31. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 1986;78:259-70.
• 32. Hollenberg SM, Dumasius A, Eassington C, Colilla SA, Neumann A, Parrillo JE. Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am J Respir Cirt Care Med 2001;164:981-5.
• 33. Wicherman KA, Baue AE, Chaudry IH. Sepsis and septic shock A review of laboratory models and a proposal. J Surg Res 1980;29:189-201.
• 34. Richmond JM, Walker JF, Avila A, Petrakis A, Finley RJ, Sibbald WJ, Linton AL. Renal and cardiovascular response to nonhypotensive sepsis in a large animal model with peritonitis. Surgery 1985;97:205-14.
• 35. Durkot MJ, Wolfe RR. Hyper and hypodynamic models of sepsis in guinea pigs. J Surg Res 1989;46:118-22.
• 36. Murakami K, Bjertnaes LJ, Schmalstieg FC, McGuire R, Cox RA, Hawkins HK, Herndon D, Traber LD, Traber DL. A novel animal model of sepsis after acute lung injury in sheep. Crit Care Med 2002;30:2083-90.
• 37. Karzai W, Cui X, Mehlhom B, Straube E, Hartung T, Gerstenberger E, Banks SM, Natanson C, Reinhart K, Eichacker PQ. Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. Anesthesiology 2003;99:81-9.
• 38. Ribes S, Domenech A, Cabellos C, Tubau F, Linares J, Viladrich PF, Gudiol F. Experimental meningitis due to a high-level cephalosporin-resistant strain of Streptococcus pneumoniae serotype 23F. Enferm Infecc Microbiol Clin. 2003;21:329-33.
• 39. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990;49:186-96.
• 40. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. Br J Surg 2001;88:22-30.
• 41. Lepper PM, Held TK, Schneider EM, Bolke E, Gerlach H, Trautmann M. Clinical implications of antiobiotic-induced endotoxin release in septic shock. Intensive Care Med 2002;28:824-33.
• 42. Michie HR. The value of animal models in the development of new drugs for the treatment of sepsis syndrome. J Antimicrob Chemother 1998;41:47-9.
• 43. Freudenberg MA, Galanos C. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in E-galactosamine treated mice. Infect Immun 1991;59:2110-5.
• 44. Hardaway RM, Williams CH, Sun Y. A new approach to the treatment of experimental septic shock. J Surg Res 1996;61:311-6.
• 45. Oud L, Haupt MT. Persistent gastric intramucosal ischemia in patients with sepsis following resuscitation from shock. Chest 1999;115:1390-6.
• 46. Doig CJ, Sutherland LR, Sandham JD, Fick GIL, Verhoef M, Meddings JB. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. Am J Respir Crit Care Med 1998;158:444-51.
• 47. Pastores SM, Katz DP, Kvetan V. Splancnic isquemia and gut injury in sepsis and the multiple organ dysfunction syndrome. Am J Gastroenterol 1996;91:1697-710.
• 48. Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: An abbreviated review. Crit Care Med 1996;24:1072-8.
• 49. Freise H. Animal models of sepsis. J Invest Surg 2001;14:195-212.

1

Trabalho realizado no Serviço de Fisiologia Aplicada, InCor, Instituto do Coração, Faculdade de Medicina da Universidade de São Paulo (FMUSP).

Publication Dates

• Publication in this collection
  20 Mar 2006
• Date of issue
  Apr 2004

History

• Reviewed
  04 Jan 2004
• Received
  21 Dec 2003
• Accepted
  19 Jan 2004